The team at Isomerase is pleased to report that Neurovive Pharmaceutical have been awarded a funding to support development of NV354, a novel treatment for mitochondrial genetic disorders that was discovered through the close research collaboration between the two companies. The grant for up to SEK 5 million is to advance the candidate compound to clinical studies.
Dr Steven Moss, Chief Technology Officer of Isomerase, said “This grant validates some of the exciting science that has come out of the partnership with Neurovive. This successful project has led to many compounds that are of significant interest. In addition to this recent grant, the science has led to a $4 million research grant for the Children’s Hospital of Philadelphia and an out-license from Neurovive to BridgeBio of specific compounds for the treatment of the eye disorder LHON”.
Earlier this year, NeuroVive reported the first preclinical efficacy outcomes for NV354 and they have continued to see further convincing efficacy data in several different established experimental models of mitochondrial disorders. Apart from NeuroVive’s own research, independent studies are underway among the company’s renowned academic partners in mitochondrial medicinal research, such as the Children’s Hospital of Philadelphia, in order to obtain additional valuable data prior to the clinical development of NV354.